Animalcare Group Plc (ANCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Animalcare Group Plc (ANCR) has a cash flow conversion efficiency ratio of 0.042x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX4.80 Million ≈ $583.66 USD) by net assets (GBX113.25 Million ≈ $13.78K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Animalcare Group Plc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Animalcare Group Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ANCR current and long-term liabilities for a breakdown of total debt and financial obligations.
Animalcare Group Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Animalcare Group Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MODERN LAND (CHINA) DL-01
F:7PJ
|
N/A |
|
Boardwalktech Software Corp
V:BWLK
|
-0.072x |
|
Cyber Media (India) Limited
NSE:CYBERMEDIA
|
0.999x |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
0.008x |
|
Cottonindo Ariesta Tbk PT
JK:KPAS
|
-0.007x |
|
NorCom Information Technology GmbH & Co. KGaA
XETRA:NC5A
|
0.063x |
|
Aethlon Medical Inc
NASDAQ:AEMD
|
0.000x |
|
Lyc Healthcare Bhd
KLSE:0075
|
2.300x |
Annual Cash Flow Conversion Efficiency for Animalcare Group Plc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Animalcare Group Plc from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Animalcare Group Plc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX113.31 Million ≈ $13.79K |
GBX11.93 Million ≈ $1.45K |
0.105x | -20.21% |
| 2023-12-31 | GBX77.89 Million ≈ $9.48K |
GBX10.28 Million ≈ $1.25K |
0.132x | +10.56% |
| 2022-12-31 | GBX78.99 Million ≈ $9.61K |
GBX9.43 Million ≈ $1.15K |
0.119x | -32.92% |
| 2021-12-31 | GBX78.80 Million ≈ $9.59K |
GBX14.02 Million ≈ $1.71K |
0.178x | +30.61% |
| 2020-12-31 | GBX81.59 Million ≈ $9.93K |
GBX11.12 Million ≈ $1.35K |
0.136x | -14.87% |
| 2019-12-31 | GBX81.89 Million ≈ $9.96K |
GBX13.11 Million ≈ $1.59K |
0.160x | +86.52% |
| 2018-12-31 | GBX86.59 Million ≈ $10.54K |
GBX7.43 Million ≈ $904.02 |
0.086x | +305.48% |
| 2017-12-31 | GBX89.64 Million ≈ $10.91K |
GBX1.90 Million ≈ $230.81 |
0.021x | -79.16% |
| 2017-06-30 | GBX23.84 Million ≈ $2.90K |
GBX2.42 Million ≈ $294.57 |
0.102x | -44.73% |
| 2016-06-30 | GBX22.52 Million ≈ $2.74K |
GBX4.14 Million ≈ $503.23 |
0.184x | -0.92% |
| 2015-06-30 | GBX20.99 Million ≈ $2.55K |
GBX3.89 Million ≈ $473.54 |
0.185x | +238.04% |
| 2014-06-30 | GBX19.45 Million ≈ $2.37K |
GBX1.07 Million ≈ $129.82 |
0.055x | -65.20% |
| 2013-06-30 | GBX17.96 Million ≈ $2.19K |
GBX2.83 Million ≈ $344.45 |
0.158x | +25.00% |
| 2012-06-30 | GBX16.84 Million ≈ $2.05K |
GBX2.12 Million ≈ $258.31 |
0.126x | -7.19% |
| 2011-06-30 | GBX15.79 Million ≈ $1.92K |
GBX2.15 Million ≈ $260.98 |
0.136x | -1.19% |
| 2010-06-30 | GBX14.08 Million ≈ $1.71K |
GBX1.94 Million ≈ $235.56 |
0.137x | -13.08% |
| 2009-06-30 | GBX15.38 Million ≈ $1.87K |
GBX2.43 Million ≈ $296.03 |
0.158x | +61.42% |
| 2008-06-30 | GBX14.64 Million ≈ $1.78K |
GBX1.44 Million ≈ $174.60 |
0.098x | -38.89% |
| 2007-06-30 | GBX6.14 Million ≈ $746.70 |
GBX984.00K ≈ $119.72 |
0.160x | +44.40% |
| 2006-06-30 | GBX5.82 Million ≈ $707.88 |
GBX646.00K ≈ $78.60 |
0.111x | +215.62% |
| 2005-06-30 | GBX5.68 Million ≈ $691.70 |
GBX200.00K ≈ $24.33 |
0.035x | -- |
About Animalcare Group Plc
Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals, and services for companion and production animals, and equine veterinary markets. The company has a collaboration with 272Bio Limited to develop and commercialize a novel biological treatment for a common equine skin condition, known as sweet itch. The company operates in Belgium, the Netherlands, the Unite… Read more